BOT has to pay substantial royalities (license payments) to their licensor. They will look to make a one-off payment to the licensor in order to reduce these royalties. It will be cheaper (but riskier) to do it now, as there is no FDA approval / USA revenue. It ultimately means they can keep more of the income from sales.
BOT has to pay substantial royalities (license payments) to...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
-0.005(1.82%) |
Mkt cap ! $425.2M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.5¢ | 26.8¢ | $632.9K | 2.342M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1822 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 281096 | 6 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
27.0¢ |
Change
-0.005 ( 0.74 %) |
||||
| Open | High | Low | Volume | ||
| 27.0¢ | 27.5¢ | 26.8¢ | 1059039 | ||
| Last updated 15.59pm 17/05/2024 ? | |||||
| BOT (ASX) Chart |